Droxidopa for Neurogenic Orthostatic Hypotension

Indications and Patient Selection

• The American College of Cardiology recommends droxidopa for treating symptomatic neurogenic orthostatic hypotension (nOH) in adults with Parkinson's disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy, though its effectiveness beyond 2 weeks remains unestablished and requires periodic reassessment 1
• Droxidopa is indicated for primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure) 2

Clinical Efficacy

• Droxidopa improves symptoms of nOH in the target populations and may reduce falls according to small studies 1, 3, 4
• The American Heart Association recommends considering droxidopa within a broader treatment algorithm for nOH, including first-line non-pharmacologic measures such as acute water ingestion, physical counter-pressure maneuvers, and compression garments 1, 3, 4

Drug Interactions and Special Populations

• Concurrent use of carbidopa may decrease droxidopa effectiveness in Parkinson's disease patients 1, 3, 4, 5, 6, 7, 2

Integration with Comprehensive nOH Management

• The American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines recommend considering droxidopa as part of a comprehensive treatment plan for nOH, including non-pharmacologic measures and other pharmacologic options such as midodrine, fludrocortisone, and salt supplementation 1, 3, 4, 6, 2